Privia Health price target raised to $32 from $30 at Jefferies

Jefferies analyst Jack Slevin raised the firm’s price target on Privia Health (PRVA) to $32 from $30 and keeps a Buy rating on the shares following an “impressive” Q4 beat. Jefferies noted momentum remains strong in their business, with recent acquisitions poised to drive incremental growth in FY26. The firm told investors that less than 16 times FY27 enterprise multiple is too cheap for a 20% plus EBITDA growth story with upside to numbers.